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Abstract 
We report the heteroditopic ligand 
H5L, which contains a DO3A unit for 
Gd
3+
 complexation connected to an 
NO2A moiety through a N-
propylacetamide linker. The synthesis 
of the ligand followed a convergent 
route that involved the preparation of 
1,4-bis(tert-butoxycarbonylmethyl)-
1,4,7-triazacyclononane following the 
orthoamide strategy. The 
luminescence lifetimes of the Tb(
5
D4) 
excited state measured for the TbL 
complex point to the absence of coordinated water molecules. Density functional theory calculations and 
1
H 
NMR studies indicate that the EuL complex presents a square antiprismatic coordination in aqueous solution, 
where eight coordination is provided by the seven donor atoms of the DO3A unit and the amide oxygen atom 
 
 
of the N-propylacetamide linker. Addition of Zn
2+
 to aqueous solutions of the TbL complex provokes a 
decrease of the emission intensity as the emission lifetime becomes shorter, which is a consequence of the 
coordination of a water molecule to the Tb
3+
 ion upon Zn
2+
binding to the NO2A moiety. The relaxivity of the 
GdL complex recorded at 7 T (25 °C) increases by almost 150% in the presence of 1 equiv of Zn
2+
, while 
Ca
2+
 and Mg
2+
 induced very small relaxivity changes. In vitro magnetic resonance imaging experiments 
confirmed the ability of GdL to provide response to the presence of Zn
2+
. 
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Introduction 
Zn
2+
 is one of the most abundant metal ions in the human body that plays a critical role acting as a structural 
component of many proteins or the active site of enzymes.
1
 Most of the Zn
2+
 present in the body is tightly 
bound in proteins, and thus the concentration of free Zn
2+
 in serum is relatively low (∼15–20 
μM).2 However, mobile Zn2+ is present at particularly high concentrations in certain organs such as brain, 
pancreas and prostate, where it plays important physiological roles.
3
 In the case of brain, chelatable Zn
2+
 is 
involved in the regulation of neuronal transmission, but both zinc overload and deficiency induce 
susceptibility to apoptosis.
4
 Failures in homeostasis of mobile Zn
2+
 have been also associated with different 
neurological diseases such as ischemia, epilepsy, Parkinson’s disease or Alzheimer’s disease.5 A class of 
glutamatergic neurons found mainly in the neo-cortex and limbic structures are susceptible to accumulate 
Zn
2+
 at high concentrations (∼1 mM). High concentrations of Zn2+ have been observed in the neo-cortex of 
Alzheimer’s disease patients together with amyloid deposits, which suggested that the amyloid pathology of 
Alzheimer’s disease arises from Zn2+ release during glutamatergic neurotransmission events.6 Thus, the 
development of probes to detect Zn
2+
 in biological systems is of great importance to shed light on the 
biological processes (pathological or not) mediated by this metal ion.
7
 
Magnetic resonance imaging (MRI) is a technique widely used by radiologists that is particularly well-suited 
for obtaining high-resolution images of soft tissues. MRI uses the 
1
H NMR signal of water molecules present 
in the body to generate contrast taking advantage of differences in the density of protons or the longitudinal 
(T1) and transverse (T2) relaxation times.
8
 Image contrast may be improved with the administration of 
contrast agents (CAs), often Gd
3+
 complexes that contain at least one water molecule coordinated to the 
metal ion exchanging rapidly with the bulk water of the body.
8,9
 These paramagnetic compounds provide an 
efficient mechanism for the longitudinal and transverse relaxation enhancement (1/T1 and 1/T2) of water 
protons, which is translated into image contrast. Responsive or smart CAs are a subclass of these 
paramagnetic probes capable of changing the T1 and/or T2 as a function of certain physiological 
parameters.
10
 Many responsive agents have been reported in the past years that are sensitive to 
temperature,
11
 pH,
12
 redox activity,
13
 enzymatic activity,
14
 or biologically relevant ions.
15
 Among these, a 
number of Zn-responsive agents with great structural variety were studied. Most commonly, a well-known 
and selective chelator N,N-bis(2-pyridyl-methyl) ethylene diamine (BPEN) was coupled to 
DTPA,
16
 DOTA,
17,18
 or porphyrins
19
 to result in potent Zn sensors. Alternatively, Zn
2+
 chelators consisting of 
substituted diacetateamine
20
 or sulfonamidoquinoline
21
 fragments, a bis(pyridinylmethyl)amine unit
22
 or an 
amidoquinoline moiety
23
 coupled to DO3A or polyamino polycarboxylates containing pyridine moieties as 
Gd
3+
-chelators were also used. 
In spite of the variety of Zn
2+
-responsive Gd
3+
-based CAs reported in the literature, some of their features are 
still to be improved. First, the relatively fast dissociation kinetics of Gd
3+
-DTPA complexes in vivo 
represents an important drawback of the first generation of responsive probes based on DTPA,
16
 as 
dissociation of the complex with Gd
3+
 release may result in undesirable side effects.
24,25
 Second, MRI has the 
intrinsic disadvantage of its low sensitivity compared to other techniques such as fluorescence.
17a
 The 
 
 
reported Zn
2+
-responsive MRI probes provide responses that fall typically within the range of 20–70% in 
terms of the relaxivity changes induced by the presence of Zn
2+
,
16-23
 although a relaxivity change of up to 
165% has been reported for a Zn
2+
 probe in the presence of human serum albumin (HSA).
17c
 However, 
improving the response of this kind of probes is highly desirable to improve the sensitivity and/or reduce the 
doses of paramagnetic agent to be injected. Third, several of the CAs responsive to Zn
2+
 present an optimal 
response at low fields (20–60 MHz),17,20b,22 while higher spatial resolution and better sensitivity is currently 
stimulating the development of high-field (3 T) and ultrahigh field (>3 T) MRI scanners.
26
 
Our groups were also involved in the development of responsive agents. A series of Gd
3+
complexes with 
mono- (H5L
1
, Chart 1) and bis-macrocyclic (H8L
2–H8L
3
) ligands providing selective and strong relaxivity 
response for Ca
2+
 over Mg
2+
 were reported by Angelovski et al.
28,27
 Besides the evaluation of the complex in 
vitro,
29
 their nanosized analogues were recently tested in vivo, exhibiting very advantageous 
properties.
30,31
 These systems contain one or two DO3A units for Gd
3+
 complexation, which are coupled to a 
non-macrocyclic Ca
2+
-binding moiety via an amide bond. This amide group is also involved in the 
coordination to Gd
3+
,
25
 thus making the whole system prone to easy coordination and thus the relaxivity 
changes. Consequently, the number of water molecules coordinated to Gd
3+
 increases in the presence of Ca
2+
, 
provoking a relaxivity increase and thus MRI response. Furthermore, the same structural motif was coupled 
to the aza-crown containing Gd
3+
 complexes, resulting in the series of neurotransmitter-sensitive contrast 
agents.
32
 
 
 
Chart 1. Chemical Structure of the Ligands Discussed in This Work
a
 
 
However, a ligand H3L
4
, which contains a TACN moiety introduced for Zn
2+
 sensing purposes, was recently 
reported by Platas-Iglesias and Tripier et al.
33
 However, Zn
2+
 addition did not provoke a change in the 
number of water molecules coordinated to Gd
3+
, although turn-on behavior of the ligand-centered 
luminescence was induced by Zn
2+
. Obviously, an appropriate nature of the Gd
3+
 chelator (DO3A unit) and 
the linker is needed to result in the potential contrast agent that will respond to the external stimulus (e.g., 
                                                          
a
 The dashed rectangles indicate the structural motif responsible for relaxivity changes in responsive CAs, while the 
dashed ellipsoids highlight the Ca
2+
- or Zn
2+
-binding motifs used in previous studies. 
 
 
change in Zn
2+
 concentration) by changing the relaxivity. Therefore, we sought to combine the successfully 
used responsive part with a Zn
2+
chelator. Thus, herein we report the heteroditopic ligand H5L, which 
contains a DO3A unit for Gd
3+
complexation linked by the same N-propylacetamide moiety to a NO2A 
moiety for Zn
2+
 binding. The GdL complex was assessed as a Zn
2+
-responsive MRI probe by using different 
spectroscopic and computational techniques. 
 
Results and Discussion 
Ligand Synthesis 
The synthesis of 1,7-bis(tert-butoxycarbonylmethyl)-1,4,7-triazacyclononane 5 was performed using a 
benzylation/dialkylation/debenzylation sequence (Scheme 1). Reaction of 1,4,7-triazacyclononane (TACN) 
with N-dimethoxymethyl-N,N-dimethylamine gave rise to the formation of the already known orthoamide 
1,4,7-triazatricyclo[5.2.1.0
4,10
]decane 1, which has been shown to be an efficient intermediary in the 
monoalkylation of TACN with halogenoalkane derivatives.
34
 Addition of benzyl bromide to 1 resulted in the 
precipitation of the corresponding ammonium salt 2 as a white powder. Acidic hydrolysis with HCl 12 
M/methanol (1/1) and further basic treatment gave the deprotected benzyl derivative 3 with 90% overall 
yield. Alkylation of the two remaining secondary amine functions proceeded in acetonitrile in the presence 
of an excess of K2CO3 by using 1.8 equiv of tert-butyl bromoacetate in order to favor the dialkylated 
product 4 instead of the quaternarization of nitrogen atoms. Derivative 4 was obtained with 63% yield after 
purification by column chromatography. Removal of the benzyl arm in the last step was performed under 
H2pressure with Pd/C (10%) in absolute ethanol to produce compound 5 (NO2AtBu) in 76% yield. This 
secondary amine was then alkylated with the bromomethyl derivative 6
28
 that carries the responsive DO3A 
moiety using K2CO3 as the base to give the bismacrocyclic compound 7. The desired chelator H5L was 
finally obtained by hydrolysis of tert-butyl esters in trifluoroacetic acid at room temperature (RT). 
 
 
Scheme 1. Synthesis of H5L
a
 
 
 
 
Complexation Studies 
To avoid problems arising from the formation of binuclear lanthanide complexes or the presence of free 
ligand, the stock solution of the ligand used for the preparation of the LnL complexes was standardized by 
titration with CuSO4·5H2O in acetate buffer (pH 5.8, Figure S1, Supporting Information). Addition of 
Cu
2+
 to a solution of the ligand results in the formation of a broad and weak absorption band at 725 nm 
attributed to d–d transitions. The titration profile shows a sharp inflection point that signals a 1:2 
stoichiometry (L/Cu), pointing to the formation of a binuclear Cu
2+
complex. Addition of an excess of metal 
ion causes a red shift of the absorption band to 742 nm due to the formation of the Cu
2+
 aqua ion. 
 
 
Figure 1. Emission spectra taken during the course of the titrations of a 1 mM solution of TbL (λexc = 230.5 nm) with a 
standard solution of Zn(CF3SO3)2 ca. 53 mM in aqueous solution at pH 7.4 (0.1 M MOPS buffer). 
 
The GdL and TbL complexes were prepared by reacting equimolar amounts of the H5L ligand and 
LnCl3·6H2O salts in aqueous solution at pH 5.8 and 80 °C for 24 h. The high-resolution mass spectra (ESI
+
) 
of the aqueous solutions of the GdL and TbL complexes show peaks due to the [GdNa2HL]
+
 and 
[NaTbH2L]
+
 entities, which indicates the formation of the mononuclear complexes (Figures S2 and 
S3, Supporting Information). The emission spectrum of the TbL complex recorded upon excitation at 230.5 
nm shows weak luminescence due to the 
5
D4 → 
7
FJ transitions characteristic of Tb
3+
 (488 nm, J = 6; 543 
nm, J = 5; 583 nm, J = 4; 618 nm, J = 3, Figure 1). The excited-state lifetimes of the TbL complex were 
measured in water (τH2O = 2.22 ms) and deuterated water (τD2O = 2.63 ms), which allows estimating the 
number of water molecules in the first coordination sphere of the metal ion according to the methodology 
developed by Horrocks,
35
 using the refined coefficients determined by Parker et al.
36
 These emission 
lifetimes provide a hydration number q = 0.05, which points to the absence of water molecules coordinated 
to the Tb
3+
 ion in aqueous solution. Both the DO3A and NO2A moieties of the ligand can in principle form 
stable complexes with the Ln
3+
 ions in aqueous solutions. However, the stability constant of the [Gd(NOTA)] 
complex (H3NOTA = 1,4,7-triazacyclononane-1,4,7-triacetic acid, log KGdL = 14.4)
37
 is 7 orders of 
magnitude lower than that of [Gd(DO3A)] (H3DO3A = 1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid, 
 
 
log KGdL = 21.0),
38
 and thus the Ln
3+
 ions in LnL complexes are expected to be coordinated to the DO3A 
unit, provided that the thermodynamic equilibrium is attained. The hydration number determined from 
luminescence lifetime measurements suggests that the Ln
3+
 ion is coordinated by the DO3A unit of the 
ligand, as [Ln(NOTA)] complexes were reported to have 2–4 coordinated water molecules.39 The absence of 
coordinated water molecules is in line with the results obtained by Parker et al. for complexes with a DO3A 
ligand containing a N-linked CH2CH2CH2NHCO–pyridyl moiety.
40
 Furthermore, the absence of inner-sphere 
water molecules points to the coordination of the amide oxygen atom of the linker to the Ln
3+
 ion, as 
proposed by Parker and co-workers for Ln
3+
 complexes containing the same linker.
40
 Coordination of the 
amide oxygen atoms was also proposed for related Ca
2+
-sensitive probes on the basis of NMR data recorded 
for the Y
3+
 complex.
27
 Indeed, the noncoordination of the amide oxygen atom would result in a coordination 
environment typical of DO3A derivatives, which contain at least a coordinated water molecule.
41
 
The 
1
H NMR spectrum of the EuL complex presents a large number of relatively broad paramagnetically 
shifted signals in the range from +25 to −20 ppm (Figure 2). In Eu3+ complexes of DOTA, DOTA–
tetraamide, and DO3A derivatives the signals of the pseudo axial protons on the cyclen rings are usually 
found between 24 and 45 ppm in the square antiprismatic (SAP) isomer and below 20 ppm in the twisted-
square antiprismatic (TSAP) isomer.
42
 These protons are observed in the range from +15 to +25 ppm for 
EuL, and therefore an unequivocal assignment of the structure of the complex in solution is not possible in 
this case. 
 
 
Figure 2. 
1
H NMR spectra of EuL recorded in D2O solution (pD = 7.0, 300 MHz, 25 °C) in the absence and in the 
presence of 1 equiv of Zn
2+
. 
 
The EuL and GdL complexes were investigated by means of density functional theory (DFT) calculations 
using the TPSSh functional and the large-core relativistic ECP of Dolg et al., following the methodology 
 
 
reported in recent computational studies (see Computational details below).
29,43
 Considering the protonation 
constants reported for TACN derivatives, this moiety is expected to be protonated at about neutral pH,
34
 and 
therefore our calculations were performed on the LnHL
+
 model systems (Ln = Eu or Gd). Geometry 
optimizations provided the expected SAP and TSAP isomers as minimum energy conformations. According 
to these computations the SAP isomer is more stable than the TSAP one, the free energy differences between 
the two forms being 10.3 (EuL) and 10.8 kJ mol
–1
 (GdL). Thus, most likely these complexes present an SAP 
coordination in aqueous solution (Figure 3). As expected due to their negative charge, the Gd–O distances 
involving oxygen atoms of carboxylate groups (2.33–2.35 Å) are shorter than the Gd–O amide distance (2.42 
Å). Overall, the distances between the Gd
3+
 ion and the ligand donor atoms are in good agreement with those 
observed for complexes of this ion with different cyclen-based ligands.
9a
 The protonated NO2A unit is 
placed above the GdDO3A entity, which likely prevents the coordination of a water molecule to the metal 
ion. This conformation appears to be stabilized by the presence of a hydrogen-bond involving the amide NH 
group and one of the nitrogen atoms of the NO2A moiety (Figure 3). 
 
 
Figure 3. Optimized geometry of the SAP isomer of GdHL
+
 obtained from DFT calculations (TPSSh/6-31G(d,p)). H 
atoms are omitted for simplicity, except those involved in hydrogen bonds. 
 
Zn
2+
 Binding Studies 
The high-resolution mass spectrometry (HR-MS) of an aqueous solution of TbL in the presence of equimolar 
Zn
2+
 presents a peak due to the [NaTbZnL]
+
 entity, which demonstrates the formation of the heterodinuclear 
complex (Figure S4, Supporting Information). Addition of Zn
2+
 to an aqueous solution of TbL at pH 7.4 (0.1 
M 3-(N-morpholino)propanesulfonic acid (MOPS) buffer) causes a decrease of the emission intensity due to 
the Tb
3+
-centered 
5
D4 → 
7
FJ transitions (Figure 1), with a sharp inflection point being observed upon addition 
of 1 equiv of Zn
2+
. Addition of an excess of the divalent metal ion does not cause further changes in the 
emission intensity nor in the emission lifetime of the 
5
D4 excited state. The emission lifetime decreases from 
2.22 to 1.37 ms upon addition of 1 equiv of Zn
2+
 in H2O solution. The emission lifetime recorded in D2O 
 
 
solution in the presence of Zn
2+
 was τD2O = 2.18 ms, which corresponds to a hydration number q = 1.07 as 
estimated by the relationship proposed by Parker.
33
 This result points to an increase of the number of 
coordinated water molecules from 0 to 1 upon Zn
2+
 binding. This suggests that the amide oxygen atom of the 
linker connecting the cyclen and TACN fragments of the ligand remains coordinated to the Ln
3+
 ion, as 
Ln
3+
 DO3A derivatives often have hydration numbers close to two.
44
 The 
1
H NMR spectrum of the EuL 
complex (Figure 2) experiences only slight changes upon Zn
2+
 addition, which also supports that the 
coordination environment of the Ln
3+
ion remains very similar. DFT calculations support this hypothesis, as 
they show that coordination of the amide group to the lanthanide ion and pentadentate coordination of 
Zn
2+
 to the NO2A moiety are feasible (Figure 4). Both metal ions are likely to complete coordination 
numbers 6 (for Zn
2+
) and 9 (for Gd
3+
) with the presence of a coordinated water molecule. Given that the 
amide oxygen atom is likely to be coordinated to the Gd
3+
 ion both in the absence and in the presence of 
Zn
2+
, the driven force behind the hydration number increase observed upon Zn
2+
 binding is not obvious. We 
hypothesize that the increased positive charge of the system upon Zn
2+
 coordination is mainly responsible for 
this effect. The absence of coordinated water molecules in the case of the charge neutral DO3A complex of 
Parker and co-workers, which contains an amide group with the same linker as L,
40
 together with the 
presence of a coordinated water molecule in a very similar Gd
3+
 complex that presents a positive 
charge,
32
 are in line with this hypothesis. 
 
 
Figure 4. Optimized geometry of the SAP isomer of GdZnL
2+
 obtained from DFT calculations (TPSSh/6-31G(d,p)). H 
atoms are omitted for simplicity, except those involved in hydrogen bonds. 
 
The efficiency of a given paramagnetic complex as an MRI contrast agent is often assessed in vitro in terms 
of relaxivity, which is defined as the longitudinal relaxation rate enhancement of water proton nuclei per 
millimolar concentration of the paramagnetic probe. The relaxivity of GdL measured at 25 °C and 7 T 
amounts to 3.08 ± 0.08 mM
–1
 s
–1
, a value that is compatible with the absence of inner sphere water 
molecules.
27,28
 As a result, the observed relaxivity arises from the outer-sphere mechanism, which is related 
to the close diffusion of outer-sphere water molecules in the vicinity of the paramagnetic center. Addition of 
 
 
Zn
2+
 induces a dramatic increase of the relaxivity, which reaches a value of 7.50 ± 0.08 mM
–1
 s
–1
 upon 
addition of 1 equiv of Zn
2+
(Figure 5). This represents almost a 150% relaxivity increase, which can only be 
explained by the coordination of a water molecule to the Gd
3+
 ion, although a contribution of second-sphere 
water molecules to the overall relaxivity cannot be ruled out.
45
 The relaxivity measured in the presence of 1 
equiv of Zn
2+
 is very similar to those reported for related Ca
2+
- and neurotransmitter-sensitive 
probes.
27,32
 Furthermore, it is lower than those observed for Ca
2+
-sensitive probes exhibiting second-sphere 
contribution to relaxivity.
45
 In those cases, the hydration numbers were confirmed with luminescence 
measurements (using both Eu
3+
 and Tb
3+
complexes) and extensive NMRD and 
17
O NMR studies, which 
provided 
17
O hyperfine coupling constants in agreement with monohydrated complexes. 
The steep curvature of the titration profile around the 1:1 (GdL/Zn
2+
) stoichiometry ratio is characteristic of 
an especially high association constant, preventing the determination of an accurate equilibrium 
constant.
46
 Interestingly, addition of Ca
2+
 or Mg
2+
 instead of Zn
2+
 causes only slight relaxivity enhancements 
(16 and 6%, respectively), which shows that the GdL probe provides selective response for Zn
2+
 over the 
main competitors in vivo. In line with these results addition of Ca
2+
 or Mg
2+
 to the TbL complex provokes 
very minor changes in the luminescence emission intensity (Figure S5, Supporting Information). 
Furthermore, the stability constants reported for complexes of the TACN derivative NOTA show that the 
complex formed with Zn
2+
 is 8–9 orders of magnitude more stable than those formed with Ca2+ and Mg2+, 
and thus the presence of these metal ions even in large excess is not expected to interfere with 
Zn
2+
 binding.
47
 As expected, relaxivity studies show that Cu
2+
 induces a relaxivity response comparable to 
that of Zn
2+
 (Figure 5), while the [Cu(NOTA)]
−
 complex was shown to be more stable than the 
Zn
2+
 analogue.
47
 However, this is likely not an important drawback for Zn
2+
 sensing in vivo, given the very 
low concentration of Cu
2+
 ion the body.
48
 
 
 
Figure 5. Relaxometric studies of GdL with endogenous cations. (left) Titration with Zn
2+
. The r1 values are 
represented as mean ± SD of three independent experiments and are normalized to [Gd
3+
] = 1 mM. (right) Competition 
experiments of Ca
2+
, Mg
2+
, or Cu
2+
 with Zn
2+
 in the presence of GdL (3 mM). Small SD values prevent visualization of 
error bars. In all cases the experiments were performed at 7 T magnetic field strength and pH 7.4 (HEPES). 
 
The relaxivity enhancement observed for GdL in the presence of Zn
2+
 was further investigated by performing 
MRI experiments with tube phantoms (Figure 6) under the same conditions as in the relaxometric studies (7 
T, pH 7.4, HEPES). For the sake of comparison, MRI experiments were also conducted using identical 
acquisition parameters and tubes with solution of GdDOTA and water as controls. In the absence of Zn
2+
, 
GdL provides less contrast enhancement, almost comparable to GdDOTA (r1 ≈ 3.9 mM
–1
 s
–1
).
49
 Addition of 
Zn
2+
 to a solution of GdL provides a clear contrast enhancement, while the presence of Zn
2+
 does not 
provoke any contrast change in the solution of GdDOTA. Finally, no contrast enhancement was observed in 
tubes that did not contain any of the Gd
3+
 complexes but only water, either in absence or presence of Zn
2+
. 
The signal-to-noise ratios (SNR) calculated for the solutions of GdL in the absence and in the presence of 
Zn
2+
 confirm the contrast enhancement (Figure 6). 
 
 
 
 
Figure 6. T1-weighted MR images obtained from the imaging scanner operating at 7 T magnetic field. (left) Solutions 
of GdL (1 mM) mixed with different concentrations of Zn
2+
 at pH 7.4 (HEPES). (right) Control experiments with 
GdDOTA (1 mM, pH 7.4, HEPES) or water in absence or presence of Zn
2+
 (1 mM). The graphs placed below the MR 
images show the SNR calculated for each of the solutions. 
 
Conclusions 
In this work we have reported the synthesis of a heteroditopic ligand that yields a MRI contrast agent 
responsive to Zn
2+
 upon Gd
3+
 complexation. A combined study including luminescence lifetime 
measurements, 
1
H NMR spectroscopy, and DFT calculations indicates octadentate coordination of the ligand 
to Gd
3+
 in GdL, which lacks inner-sphere water molecules. Coordination of Zn
2+
 to the TACN unit of the 
ligand triggers the coordination of a water molecule to Gd
3+
, resulting in a 150% relaxivity enhancement at 7 
T and 25 °C. This represents, to the best of our knowledge, the highest relaxivity response to Zn
2+
 of a 
Gd
3+
 probe at high field, although relaxivity changes as high as 200% have been reported at lower 
fields.
20b
 Furthermore, Ca
2+
 and Mg
2+
provoke very small relaxivity changes, showing that GdL provides a 
selective response toward Zn
2+
 over their main competitors. MRI studies in vitro confirmed the ability of 
GdL to provide remarkable response to Zn
2+
 in terms of an enhanced contrast. 
 
Experimental and Computational Section 
General Methods 
Reagents were purchased from commercial sources unless otherwise specified. 1,4,7-Triazacyclononane was 
purchased from CheMatech (Dijon, France). Acetonitrile, tetrahydrofuran (THF), toluene, and chloroform 
were distilled before use. Compound 6 was synthesized according to previously published procedure.
28
 ESI-
TOF mass spectra were recorded using a LC-Q-q-TOF Applied Biosystems QSTAR Elite spectrometer or a 
MAXis 4G, Bruker Daltonics Inc, Germany, using both the positive and negative modes. High-resolution 
 
 
mass spectra were recorded on a Bruker Daltonics APEX II (FT-ICR-MS) with an ESI source. UV–vis 
spectra were recorded on a PerkinElmer Lambda 900 spectrophotometer in 1.0 cm path quartz cells. 
Excitation and emission spectra were recorded on a PerkinElmer LS-50B spectrometer. Luminescence 
lifetimes were calculated from the monoexponential fitting of the average decay data, and they are averages 
of at least 3–5 independent determinations. 1H and 13C NMR spectra of organic molecules were recorded 
with a Bruker AMX-3 300 (300 MHz) or a Bruker Avance III 300 MHz spectrometer. 
1
H NMR spectra of 
the EuL complex were recorded at 25 °C on a Bruker Avance 300 MHz spectrometer. Relaxometric titrations 
were performed using a Bruker Avance III 300 MHz spectrometer. Magnetic resonance imaging experiments 
at field strength of 7 T were performed on a BioSpec 70/30 USR magnet using Bruker quadrature volume 
coil (RF RES 300 1H 112/86 QSN TD AD). 
1-Benzyl-[1,4,7]-triazacyclononane (3) 
N-Dimethoxymethyl-N,N-dimethylamine (670 mg, 5.60 mmol, 1.1 equiv) was added to a solution of TACN 
(660 mg, 5.10 mmol) in chloroform (1 mL) and toluene (10 mL). The solution was stirred at RT for 12 h. 
The solvent was then evaporated under reduced pressure to yield an oily product. Benzyl bromide (1.1 equiv, 
5.62 mmol, 670 μL) in solution in 15 mL of freshly distilled THF was added to the previous crude product. 
The precipitated white solid was filtered after the mixture was stirred at RT for 3 d, washed with THF, and 
dried under vacuum. The white solid was dissolved in 10 mL of a solution of methanol/HCl 12 M (1:1) and 
stirred at reflux for 12 h. After it cooled, the pH was raised to 12 by addition of NaOH pellets. Extraction 
with chloroform (3 × 15 mL), drying with MgSO4, and evaporation of the solvent under reduced pressure 
gave the 1-benzyl-1,4,7-triazacyclononane 3 as a yellow oil (1.01g, 4.60 mmol, 90%). 
1
H NMR (300 MHz, 
CDCl3): δ 2.53 (m, 8H, CH2TACN), 2.80 (s, 4H, CH2TACN), 3.07 (s, 2H, NH), 3.60 (s, 2H, CH2Ph), 7.12–7.23 
(m, 5H, C6H5). 
13
C NMR (75 MHz, CDCl3): δ 46.1, 46.2, 52.3, 61.2, 126.7, 127.9, 128.6, 139.2. 
(4-Benzyl-7-tert-butoxycarbonylmethyl-[1,4,7]-triazonan-1-yl)-acetic acid tert-butyl ester (4) 
Compound 3 (1.01g, 4.60 mmol) was dissolved in 15 mL of freshly distilled acetonitrile, and 1.8 equiv 
of tert-butyl bromoacetate (1.61 g, 8.28 mmol) and K2CO3 (excess) were added. After it was stirred at RT for 
4 d, the solution was filtered. Evaporation of the solvent gave an oily crude product. Purification was 
performed by chromatography on silica gel (elution with hexanes/CHCl32:1, Rf = 0.7). Compound 4 was 
obtained as a clear oil (1.30 g, 2.90 mmol, 63%). 
1
H NMR (300 MHz, CDCl3): δ 1.42 (s, 18H, C(CH3)3), 
2.78 (bs, 4H, CH2TACN), 2.81 (bs, 4H, CH2TACN), 2.92 (s, 4H, CH2TACN), 3.28 (s, 4H, CH2CO2tBu), 3.65 (s, 
2H, CH2Ph), 7.14–7.32 (m, 5H, C6H5). 
13
C NMR (75 MHz, CDCl3): δ 28.2, 55.2, 55.3, 55.6, 59.9, 62.6, 80.4, 
126.6, 128.0, 128.9, 140.2, 171.4. 
(4-tert-Butoxycarbonylmethyl-[1,4,7]-triazonan-1-yl)-acetic acid tert-butyl ester (5): NO2A
t
Bu 
Compound 4 (1.30 g, 2.90 mmol) was dissolved in absolute ethanol, and 10% Pd/C activated was added. The 
reaction mixture was left under hydrogen atmosphere at RT under stirring for 4 d. After filtration through 
Celite, ethanol was removed by evaporation at reduced pressure to produce 5 as a yellow oil (790 mg, 2.21 
mmol, 76%). 
1
H NMR (300 MHz, CDCl3): δ 1.40 (s, 18H, C(CH3)3), 2.71 (s, 4H, CH2TACN), 3.01 (m, 4H, 
CH2TACN), 3.19 (m, 4H, CH2TACN), 3.32 (s, 4H, CH2CO2tBu). 
13
C NMR (75 MHz, CDCl3): δ 28.1, 44.5, 49.2, 
51.9, 56.7, 81.8, 170.7. 
(4-{3-[2-(4,7-Bis-tert-butoxycarbonylmethyl-[1,4,7]-triazonan-1-yl)-acetylamino]-propyl}-7,10-bis-tert-
butoxycarbonylmethyl-1,4,7,10-tetraaza-cyclododec-1-yl)-acetic acid tert-butyl ester (7) 
The bromide 6 (750 mg, 1.05 mmol) was dissolved in acetonitrile (5 mL) and added slowly to the suspension 
of the azamacrocycle 5 (320 mg, 0.90 mmol) and potassium carbonate (371 mg, 2.69 mmol) in acetonitrile 
(20 mL). The reaction mixture was stirred at 70 °C for 16 h. After it cooled, the mixture was filtered, and the 
solvent was evaporated under reduced pressure. The residue was purified using column chromotography 
 
 
(silica gel, 5% methanol/dichloromethane, Rf = 0.3) to give compound 7 as a light brown solid (330 mg, 0.34 
mmol, 38%). 
1
H NMR (300 MHz, CDCl3): δ 1.41 (s, 9H, CH3), 1.42 (s, 18H, CH3), 1.48 (s, 18H, CH3), 1.77 
(br, 2H, CH2), 1.95−3.73 (br, 42H, CH2), 4.10 (s, 2H, CH2), 9.02 (s, 1H, NH). 
13
C NMR (75 MHz, CDCl3): δ 
24.3, 27.3, 27.5, 27.7, 37.2, 48.3, 50.0, 51.4, 51.7, 52.9, 55.2, 56.0, 56.4, 81.5, 82.1, 82.4, 169.3, 169.5, 
171.0, 173.0. ESI-HRMS (m/z): [M + H]
+
 calcd. for C49H93N8O11
+
, 969.6958, found 969.6950, [M + 
Na]
+
 calcd. for C49H92N8NaO11
+
, 991.6778, found 991.6768. 
(4-{3-[2-(4,7-Bis-carboxymethyl-[1,4,7]triazonan-1-yl)-acetylamino]-propyl}-7,10-bis-carboxymethyl-
1,4,7,10-tetraaza-cyclododec-1-yl)-acetic acid (L) 
Compound 7 (0.33 mmol, 300 mg) was dissolved in anhydrous dichloromethane (5 mL), and the solution 
was cooled to 0 °C. Trifluoroacetic acid (TFA; 5 mL) was slowly added, and the solution was stirred at RT 
for 16 h. The reaction mixture was concentrated under reduced pressure, and the residue was dissolved in a 
small portion of methanol. The product was precipitated from diethyl ether, isolated by decantation, and 
dried under reduced pressure to give H5L·5CF3COOH as a pale brown hygroscopic solid (300 mg, 73%). 
1
H 
NMR (300 MHz, D2O): δ 1.84−2.03 (br, 2H, CH2), 2.73−4.13 (br, 44H, CH2). 
13
C NMR (75 MHz, D2O): δ 
23.2, 35.9, 36.6, 48.6, 48.9, 49.5, 49.9, 50.7, 51.3, 51.9, 53.3, 53.5, 55.7, 56.6, 58.9, 60.9, 116.3 (TFA), 162.9 
(TFA), 169.8, 172.7, 172.8, 174.1, 175.1. ESI-HRMS (m/z): [M + H]
+
 calcd. for C29H53N8O11
+
, 689.3828, 
found 689.3830. 
Computational Details 
All calculations reported in this work were performed employing the Gaussian 09 package (Revision 
D.01).
50
 Full geometry optimizations of the LnHL
+
 and LnZnL
2+
 systems were performed in aqueous 
solution employing DFT within the hybrid meta-generalized gradient approximation (hybrid meta-GGA), 
with the TPSSh exchange-correlation functional.
51
 Geometry optimizations were performed by using the 
large-core quasirelativistic effective core potential of Dolg and coworkers and its associated [5s4p3d]-GTO 
valence basis set,
52
 while the ligand atoms and Zn were described by using the standard 6-31G(d,p) basis set. 
No symmetry constraints were imposed during the optimizations. The stationary points found on the 
potential energy surfaces as a result of geometry optimizations were tested to represent energy minima rather 
than saddle points via frequency analysis. The default values for the integration grid (75 radial shells and 302 
angular points) and the self-consistent field energy convergence criteria (1 × 10
–8
) were used in all 
calculations. Solvent effects were included by using the integral equation formalism of the polarizable 
continuum model as implemented in Gaussian 09.
53
 
Relaxometric Experiments 
For titration experiments, a solution of ZnCl2 of known concentration was added stepwise to a solution of 
GdL (starting concentration 3.0 mM), and the longitudinal proton relaxation time T1 was measured after each 
addition of the analyte. The 
1
H relaxivity r1 was calculated from the eq 1/T1,obs = 1/T1,d + r1 × [Gd
3+
], 
where T1,obs is the observed longitudinal relaxation time, T1,d is the diamagnetic contribution in the absence of 
the paramagnetic substance, and [Gd
3+
] is the actual concentration of Gd
3+
 at each point of the titration. The 
initial Gd
3+
 concentrations were determined by measuring the bulk magnetic susceptibility shifts.
54
 The 
concentration of 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer was 50 mM. The 
reported values are mean values of three independent experiments. 
Competition experiments were performed in a similar fashion. The longitudinal proton relaxation 
time T1 was measured for the solution of GdL (starting concentration 3.0 mM) alone, and then after addition 
of the following solutions: CaCl2, MgCl2, or CuSO4 (2 × 1 equiv). The final values were measured upon 
addition of ZnCl2 (2 equiv) to these mixtures. 
 
 
 
Magnetic Resonance Imaging Experiments 
1
H MRI was performed on two sets of probes: (1) A solution of GdL (1 mM) to which 0, 0.33, 0.66, and 1 
equiv of Zn
2+
 were added; (2) solutions of Dotarem (1 mM) in absence and presence of Zn
2+
 (1 equiv), or 
water without or with Zn
2+
 (1 mM). These sets were placed in 4 × 200 μL plastic tubes and inserted in the 20 
mL syringe filled with water and 162 mM of Dotarem to avoid susceptibility artifacts. 
1
H T1 images were 
acquired using the fast low angle shot pulse sequence: field-of-view = 40 × 40 mm
2
, matrix size = 512 × 512, 
one slice, slice thickness 1 mm, flip angle = 90 
o
, echo time = 3.0 ms, repetition time = 60.0 ms, number of 
averages = 4. The total acquisition time was 1m 1s 440 ms. 
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